Wall Street analysts predict that Inogen Inc (NASDAQ:INGN) will post $0.52 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Inogen’s earnings, with estimates ranging from $0.48 to $0.58. Inogen posted earnings per share of $0.33 during the same quarter last year, which indicates a positive year over year growth rate of 57.6%. The business is expected to report its next earnings results on Tuesday, November 6th.

On average, analysts expect that Inogen will report full year earnings of $2.07 per share for the current financial year, with EPS estimates ranging from $2.01 to $2.12. For the next financial year, analysts expect that the company will report earnings of $2.17 per share, with EPS estimates ranging from $1.97 to $2.27. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Inogen.

Inogen (NASDAQ:INGN) last posted its earnings results on Tuesday, August 7th. The medical technology company reported $0.65 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.44 by $0.21. Inogen had a net margin of 10.39% and a return on equity of 16.51%. The company had revenue of $97.24 million for the quarter, compared to analyst estimates of $81.61 million.

A number of equities research analysts recently weighed in on INGN shares. Stifel Nicolaus set a $258.00 target price on shares of Inogen and gave the stock a “buy” rating in a report on Tuesday, August 21st. Zacks Investment Research upgraded shares of Inogen from a “hold” rating to a “buy” rating and set a $262.00 target price on the stock in a report on Wednesday, August 22nd. BidaskClub lowered shares of Inogen from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 31st. Needham & Company LLC restated a “buy” rating on shares of Inogen in a report on Wednesday, June 13th. Finally, KeyCorp started coverage on shares of Inogen in a report on Wednesday, June 6th. They issued an “equal weight” rating on the stock. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $245.00.

Shares of INGN traded up $5.70 on Tuesday, reaching $258.66. The company’s stock had a trading volume of 232,400 shares, compared to its average volume of 193,425. Inogen has a twelve month low of $91.80 and a twelve month high of $287.79. The firm has a market capitalization of $5.44 billion, a PE ratio of 197.45, a P/E/G ratio of 5.03 and a beta of 1.22.

In other Inogen news, insider Matt Scribner sold 2,000 shares of the stock in a transaction dated Monday, September 17th. The shares were sold at an average price of $281.23, for a total value of $562,460.00. Following the completion of the sale, the insider now owns 7,595 shares in the company, valued at approximately $2,135,941.85. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Byron Myers sold 24,953 shares of the stock in a transaction dated Thursday, August 9th. The shares were sold at an average price of $227.13, for a total transaction of $5,667,574.89. Following the completion of the sale, the executive vice president now owns 42,329 shares of the company’s stock, valued at approximately $9,614,185.77. The disclosure for this sale can be found here. Insiders sold a total of 106,308 shares of company stock worth $23,498,421 in the last 90 days. 5.29% of the stock is currently owned by company insiders.

Large investors have recently bought and sold shares of the business. Catalyst Capital Advisors LLC purchased a new stake in Inogen in the 2nd quarter valued at about $112,000. Advisors Preferred LLC purchased a new stake in Inogen in the 2nd quarter valued at about $176,000. SG Americas Securities LLC purchased a new stake in Inogen in the 1st quarter valued at about $178,000. Thompson Siegel & Walmsley LLC purchased a new stake in Inogen in the 2nd quarter valued at about $186,000. Finally, Raymond James Financial Services Advisors Inc. purchased a new stake in Inogen in the 2nd quarter valued at about $216,000. Hedge funds and other institutional investors own 96.47% of the company’s stock.

About Inogen

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

See Also: What does RSI mean?

Get a free copy of the Zacks research report on Inogen (INGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.